Plasma Thrombomodulin Levels and Ischemic Stroke

Authors:
  • DGDaoxia Guo
    Daoxia Guo
  • YJYiming Jia
    Yiming Jia
  • KZKaixin Zhang
    Kaixin Zhang
  • MSMengyao Shi
    Mengyao Shi
  • YPYanbo Peng
    Yanbo Peng
  • PYPinni Yang
    Pinni Yang
  • JCJing Chen
    Jing Chen
  • JZJintao Zhang
    Jintao Zhang
  • AWAili Wang
    Aili Wang
  • TXTan Xu
    Tan Xu

Abstract
Background and Objectives: Thrombomodulin has been suggested to be implicated in ischemic stroke due to its anticoagulant, anti-inflammatory, and cytoprotective properties. We aimed to investigate the associations of plasma thrombomodulin levels with clinical outcomes after ischemic stroke in a multicenter prognostic cohort study. Methods: Our multicenter prognostic cohort study included 3532 Chinese ischemic stroke patients from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was the composite outcome of death and major disability (modified Rankin scale [mRS] score ≥3) at 3 months after ischemic stroke. Secondary outcomes included major disability (mRS score, 3-5), vascular events, and the ordered 7-level categorical score of the mRS. Results: During 3 months of follow-up, 867 participants experienced primary outcome. After multivariate adjustment, the adjusted odds ratios or hazard ratios associated with highest quartile of plasma thrombomodulin were 0.75 (95% CI, 0.59-0.97; ptrend=0.029) for primary outcome, 0.73 (95% CI, 0.56-0.94; ptrend=0.028) for major disability, and 0.80 (95% CI, 0.42-1.51; ptrend=0.232) for vascular events. In addition, a significantly better shift in the distribution of mRS score was observed with higher thrombomodulin quartiles (ptrend=0.005). Multivariable-adjusted spline regression model showed a linear relationship between plasma thrombomodulin and the risk of primary outcome (p for linearity=0.027). Subgroup analyses further confirmed these associations. Discussion: Increased plasma thrombomodulin levels at baseline were associated with decreased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting a protective role of thrombomodulin in the development of ischemic stroke. Further studies from various populations are needed to replicate our findings.